Psoriasis: risankizumab tops adalimumab in phase 3 trial

  • Lancet

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Risankizumab (Skyrizi) shows superior efficacy to adalimumab (Humira) in patients with moderate-to-severe plaque psoriasis, according to the multinational phase 3 IMMvent trial.

Why this matters

  • This is the first head-to-head trial comparing these 2 biologic therapies for psoriasis.

Key results

  • Risankizumab was associated with better efficacy compared with adalimumab at week 16.
    • 72% vs 47% of patients achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI-90) (P<.0001>
    • 84% vs 60% of patients achieved static Physician’s Global Assessment (sPGA) scores of clear or almost clear (P<.0001>
  • Adalimumab intermediate responders who switched to risankizumab at week 16 showed a higher PASI 90 rate (66% vs 21%; P<.0001 and spga clear rate vs compared with patients who continued adalimumab at week>
  • Risankizumab and adalimumab were associated with similar rates of adverse events at week 16 (56% vs 57%).

Study design

  • 605 patients with moderate-to-severe plaque psoriasis were randomly assigned to risankizumab (n=301) or adalimumab (n=304) through 16 weeks.
  • At week 16, 102 patients with an intermediate response to adalimumab were re-randomly assigned to risankizumab (n=51) or adalimumab (n=51) through week 44.
  • Funding: AbbVie, Boehringer Ingelheim.

Limitations

  • Prolonged interval between final dose and final assessment.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit